Proliferative effect of apidra® (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells

Archives of Physiology and Biochemistry

Volumn 115, Issue 3, 2009, Pages 119-126

  Shukla, Ashish ^a   Enzmann, Harald ^b   Mayer, Doris ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

Author keywords

Insulin; Insulin glulisine; Mammary epithelial cells; Proliferation; Signalling pathways

Indexed keywords

DRUG DERIVATIVE; INSULIN; RECOMBINANT PROTEIN; SOMATOMEDIN C RECEPTOR;

ANIMAL; ARTICLE; CATTLE; CELL LINE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; EPITHELIUM CELL; FEMALE; GENETICS; HUMAN; MAMMARY GLAND; METABOLISM; PATHOLOGY; UDDER;

ANIMALS; CATTLE; CELL LINE; CELL PROLIFERATION; EPITHELIAL CELLS; FEMALE; HUMANS; INSULIN; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS;

EID: 73949128030     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450903008628     Document Type: Article

References (35)

1. Becker RH. (2007). Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther 9:109-21.
2. Belfiore A, Frasca F. (2008). IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:381-406.
3. Blundell T, Dodson GG, Cutfield JM, Cutfield SM. (1972). Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26:279-402.
4. Brange J, Volund A. (1999). Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307-35.
5. Brooks SC, Locke ER, Soule HD. (1973). Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem 248:6251-3.
6. Dideriksen LH, Jorgensen LN, Drejer K. (1992). Carcinogenic effect on female rats after 12 months administration of the insulin B10ASP. Abstract. Diabetes 41:143A.
7. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH, Sussenbach JS. (1997). Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 272:31163-71.
8. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. (2008). The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 114:23-37.
9. Gammeltoft S, Hansen BF, Dideriksen L, Lindholm A, Schaffer L, Trub T, Dayan A, Kurtzhals P. (1999). Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opin Investig Drugs 8:1431-42.
10. Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D. (2007). Glycogen synthase kinase-3 protects estrogen receptor-α from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 21:2427-39.
11. Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, Klein HH, Lundemose AG. (1996). Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271-9.
12. Hennige AM, Strack V, Metzinger E, Seipke G, Häring HU, Kellerer M. (2005). Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 48:1891-7.
13. Jhun BH, Meinkoth JL, Leitner JW, Draznin B, Olefsky JM. (1994). Insulin and insulin-like growth factor-I signal transduction requires p21ras. J Biol Chem 269:5699-704.
14. Knowles BB, Howe CC, Aden DP. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-9.
15. Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005.
16. Liefvendahl E, Arnqvist HJ. (2008). Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369-74.
17. Lu K, Campisi J. (1992). Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB/c murine fibroblasts. Proc Natl Acad Sci USA 89:3889-93.
18. Mathupala SP, Rempel A, Pedersen PL. (1997). Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 9:339-43.
19. Mayer D, Shukla A, Enzmann H. (2008). Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38-44.
20. Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. (2005). Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor-α and is involved in the regulation of receptor activity. J Biol Chem 280:33006-14.
21. Mehta RG, Hawthorne ME, Steele VE. (1997). Induction and prevention of carcinogen-induced precancerous lesions in mouse mammary gland organ culture. Meth Cell Sci 19:19-24.
22. Niemeyer H, Ureta T, Clark-Turri L. (1975). Adaptive character of liver glucokinase. Mol Cell Biochem 6:109-126.
23. Pollak MN, Schernhammer ES, Hankinson SE. (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518.
24. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. (2003). A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227-38.
25. Rempel A, Bannasch P, Mayer D. (1994a). Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. Biochem J 303:269-74.
26. Rempel A, Bannasch P, Mayer D. (1994b). Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219:660-8.
27. Reynolds NA, Wagstaff AJ. (2004). Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 64:1957-74.
28. Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. (2000). Downregulation of insulin-like growth factor-1 receptor and insulin receptor substrate-1 in advanced human breast cancer. Int J Cancer (Pred Oncol). 89:506-13.
29. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. (2009). Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-41.
30. Shymko RM, Dumont E, De Meyts P, Dumont JE. (1999). Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 339:675-83.
31. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, et al. (1997). Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40 (Suppl 2):S54-61.
32. Soule HD, Maloney TM, Wolman SR, Peterson Jr WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. (1990). Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6075-86.
33. Stammberger I. (2006). Insuline glulisine - A comprehensive pre-clinical evaluation. Int J Toxicol 25:24-33.
34. Vajo Z, Duckworth WC. (2000). Genetically engineered insulin analogs: diabetes in the new millennium. Pharmacol Rev 52:1-9.
35. Wilde MI, McTavish D. (1997). Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54:597-614.